Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 10

1.

Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients.

Giovannoni G, Cohen JA, Coles AJ, Hartung HP, Havrdova E, Selmaj KW, Margolin DH, Lake SL, Kaup SM, Panzara MA, Compston DA; CARE-MS II Investigators.

Neurology. 2016 Nov 8;87(19):1985-1992. Epub 2016 Oct 12.

2.

Preclinical Studies of a Kidney Safe Iodinated Contrast Agent.

Rowe ES, Rowe VD, Biswas S, Mosher G, Insisienmay L, Ozias MK, Gralinski MR, Hunter J, Barnett JS.

J Neuroimaging. 2016 Sep;26(5):511-8. doi: 10.1111/jon.12356. Epub 2016 May 12.

3.

Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial.

Cohen JA, Coles AJ, Arnold DL, Confavreux C, Fox EJ, Hartung HP, Havrdova E, Selmaj KW, Weiner HL, Fisher E, Brinar VV, Giovannoni G, Stojanovic M, Ertik BI, Lake SL, Margolin DH, Panzara MA, Compston DA; CARE-MS I investigators.

Lancet. 2012 Nov 24;380(9856):1819-28. doi: 10.1016/S0140-6736(12)61769-3. Epub 2012 Nov 1.

PMID:
23122652
4.

Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial.

Coles AJ, Twyman CL, Arnold DL, Cohen JA, Confavreux C, Fox EJ, Hartung HP, Havrdova E, Selmaj KW, Weiner HL, Miller T, Fisher E, Sandbrink R, Lake SL, Margolin DH, Oyuela P, Panzara MA, Compston DA; CARE-MS II investigators.

Lancet. 2012 Nov 24;380(9856):1829-39. doi: 10.1016/S0140-6736(12)61768-1. Epub 2012 Nov 1.

PMID:
23122650
5.

Rotigotine improves restless legs syndrome: a 6-month randomized, double-blind, placebo-controlled trial in the United States.

Hening WA, Allen RP, Ondo WG, Walters AS, Winkelman JW, Becker P, Bogan R, Fry JM, Kudrow DB, Lesh KW, Fichtner A, Schollmayer E; SP792 Study Group.

Mov Disord. 2010 Aug 15;25(11):1675-83. doi: 10.1002/mds.23157.

PMID:
20629075
6.

Long-term maintenance treatment of restless legs syndrome with gabapentin enacarbil: a randomized controlled study.

Bogan RK, Bornemann MA, Kushida CA, TrĂ¢n PV, Barrett RW; XP060 Study Group.

Mayo Clin Proc. 2010 Jun;85(6):512-21. doi: 10.4065/mcp.2009.0700. Erratum in: Mayo Clin Proc. 2010 Jul;85(7):693-4.

7.
8.

Cockayne syndrome: an atypical case.

Kennedy RM, Rowe VD, Kepes JJ.

Neurology. 1980 Dec;30(12):1268-72.

PMID:
7192807
9.

Urinary metabolites of phenylalanine in the preweanling rat treated with p-chlorophenylalanine and phenylalanine.

Rowe VD, Fales HM, Pisano JJ, Andersen AE, Guroff G.

Biochem Med. 1975 Feb;12(2):123-36. No abstract available.

PMID:
124572
10.

Some characteristics of the p-chlorophenylalanine-induced cataract.

Rowe VD, Zigler S, Andersen AE, Sidbury JB, Guroff G.

Exp Eye Res. 1973 Nov 11;17(3):245-50. No abstract available.

PMID:
4271802

Supplemental Content

Loading ...
Support Center